Raphael Pharmaceutical INC 10-Q quarterly reports

Raphael Pharmaceutical Inc. reported a reduced net loss for the second quarter of 2026, but continues to face significant financial challenges and substantial doubt regarding its ability to continue as a going concern.

Raphael Pharmaceutical Inc. reported a reduced net loss of $229,000 for Q1 2026, a 47% decrease from the prior year, driven by lower R&D and G&A expenses, though the company continues to face going concern uncertainties.

Raphael Pharmaceutical Inc. reports significant liquidity challenges and a going concern warning despite positive clinical study results and a new product launch.

Raphael Pharmaceutical Inc. reported continued net losses and a going concern warning, despite launching its RaphaWell formula for rheumatoid arthritis support as a dietary supplement.

Raphael Pharmaceutical Inc.'s Q1 2025 results show a decrease in research and development expenses offset by an increase in general and administrative costs, with the company continuing to focus on cannabinoid-based drug development.

Raphael Pharmaceutical Inc. reported a decrease in operating loss for the third quarter of 2024, driven by reduced research and development expenses, as the company continues its clinical development programs.

Raphael Pharmaceutical Inc. reported a net loss of $798,000 for the six months ended June 30, 2024, as the company continues to invest in research and development.

Raphael Pharmaceutical Inc. reported a significant increase in research and development expenses and a larger net loss for the first quarter of 2024 compared to the same period last year.